NCT06619886View on ClinicalTrials.gov

TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor

EARLY_PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

September 24, 2024

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2027

Conditions
Solid Tumor, AdultLung AdenocarcinomaPancreas CancerColorectal CancerOther Solid Tumor
Interventions
BIOLOGICAL

Autologous, engineered T Cells targeting TP53 R248Q

TP53-R248Q mutant TCR-T Cells Injection, 28 days as a treatment cycle (cycle number N≤3), each cycle was divided into three D0, D7, D14 infusion, a total of 3 dose groups were set up, the single infusion of cells within the range of ±20% all meet the requirements

Trial Locations (1)

200080

Department of Oncology, Shanghai General Hospital, Shanghai

All Listed Sponsors
lead

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

NCT06619886 - TP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor | Biotech Hunter | Biotech Hunter